Well 6% clinical heart failure is up there as well as 18% for sub clinical over a study of 49000 patients I do concur
Currently high dose Liposomal or dexrazoxane and the not so liked due to studies so far with ACE inhibitors are there… R220 may have a place in the line up but to the dislike of many here my opinion is it won’t be used in every dose of Dox like your paid report alludes!!
All my opinion quite happy for you to disagree…. And this is where I make my rational judgement
Industry news, page-1880
-
- There are more pages in this discussion • 526 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |